Glycemic control and pulmonary function sustained throughout long-term use of inhalable insulin

Zepbound, which was approved last month to treat obesity, is now available in U.S. pharmacies.

Shortages are growing because of disruption caused natural disasters and ingredient supply issues, as well as increased demand for certain drugs.

Twice-daily danuglipron was being studied in a phase 2 study in adults with obesity. Pfizer is now conducting a pharmacokinetic study for a once-daily formulation.

A new survey finds that more people are using semaglutide and other GLP-1 therapies to lose less than 15 pounds.

Patients taking Mounjaro after a lifestyle intervention saw a weight reduction of almost 20%.

Svetlana Mojsov, Ph.D., was a key part of the team that discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss.